On February 21, 2023 Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, reported that it will release 2H & FY 2022 Report on Thursday, March 2, 2023, at 08:00 EET/ 07:00 CET (Press release, Herantis Pharma, FEB 21, 2023, View Source;invitation-to-2h—fy-2022-report-webinar-on-march-2–2023,c3719979 [SID1234627441]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Members of the Herantis’ Management team will hold a live webinar to provide more details on the 2H & FY 2022 Report with a live Q&A session (in English) at 10:00 EET / 9:00 CET on the same day.
Please join the webinar a few minutes in advance.
Register for Herantis Pharma’s 2H & FY 2022 Report webinar here: Click Here to Register
Registation is required for this event. To register for this event you need a Zoom account. After registering, you will receive a confirmation email containing information about joining the webinar.
Questions can be submitted throughout the webcast event.
Following the webcast of the live call, a recording will be available on Herantis Pharma’s website:View Source
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: [email protected]
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
Company website: www.herantis.com